Anti-Nanog (AMAb91393) monoclonal antibody in ovarian cancer study

Article: "MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer"

MET expression and cancer stem cell networks impact the outcome in high-grade serous ovarian cancer (Genes, 2021).

Overexpression of the receptor tyrosine kinase MET has been linked to poor survival in several cancer types, such as ovarian or fallopian tube cancer that accounts for 4.7% of all cancer-related deaths in women.

This study shows that MET expression represents a prognostic tool for high-grade serous cancer (HGSC), the most common ovarian/fallopian tube cancer.

Our anti-Nanog (AMAb91393) monoclonal antibody is here used, among others, as a stem cell marker for MET mRNA/protein expression comparison in cancerous cell lines.

Read full article here.

Find out more about our Anti-Nanog (AMAb91393) monoclonal antibody.